Clinical trials: sponsored by M.D. Anderson Cancer Center
Lung Cancer
A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation
This is a phase II, single-arm, open-label study evaluating the efficacy, safety and tolerability of neoadjuvant sotorasib in combination with cisplatin (or carboplatin) and pemetrexed chemotherapy for patients with surgically…
- Trial name
- NCT05118854
- Testing
- AMG 510, Cisplatin, Carboplatin
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- M.D. Anderson Cancer Center
Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma
Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma
This phase II trial studies how well acalabrutinib, lenalidomide, and rituximab work in treating patients with CD20 positive stage III-IV, grade 1-3a follicular lymphoma.
- Conditions
- Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma
- Trial name
- NCT04404088
- Testing
- Acalabrutinib, Lenalidomide, Rituximab
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Myeloid Leukemia
Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
To learn if asciminib can help to control CML. The safety and effects of this drug will also be studied.
- Trial name
- NCT06236724
- Testing
- Asciminib
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- M.D. Anderson Cancer Center
Stage 4 NSCLC
Universal Immunization to Fortify Immunotherapy Efficacy and Response
Although immune checkpoint inhibitors (ICIs) have substantially extended survival in many patients, most patients do not achieve durable responses on these treatments.
- Trial name
- UNIFIER (NCT07597070)
- Testing
- Pfizer-BioNTech mRNA COVID-19 vaccine
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- University of Florida
Adenoid Cystic Carcinoma
Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Carcinoma Subtype I (ACC-I)
Phase II open label study designed to evaluate the efficacy and safety of P-Sam in patients with aggressive, solid, NOTCH mutant or p63 low (B7-H4 high) R/M ACC-I patients.
- Trial name
- NCT07162480
- Testing
- P-Sam
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- M.D. Anderson Cancer Center
Cardiomyopathy, Heart Failure
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
This randomized pilot phase I trial studies the side effects of donor bone marrow derived mesenchymal stem cells in controlling heart failure in patients with cardiomyopathy caused by anthracyclines.
- Conditions
- Cardiomyopathy, Heart Failure, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT02962661
- Testing
- Best Practice, Laboratory Biomarker Analysis, Mesenchymal Stem Cell Transplantation
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- M.D. Anderson Cancer Center
Philadelphia Chromosome-Positive, Acute Lymphoblastic Leukemia
Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
To learn if the combination of blinatumomab and asciminib can help to control Ph+ ALL.
- Trial name
- NCT06308588
- Testing
- Blinatumomab, Asciminib
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia
Personalized NK Cell Therapy in CBT
This phase II clinical trial studies how well personalized natural killer (NK) cell therapy works after chemotherapy and umbilical cord blood transplant in treating patients with myelodysplastic syndrome, leukemia, lymphoma or…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission
- Trial name
- NCT02727803
- Testing
- Allogeneic Natural Killer Cell Line NK-92, Anti-Thymocyte Globulin, Busulfan
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Mantle Cell Lymphoma
GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma
Primary Objectives: To estimate the percent of participants who achieve a best response of complete response by the end of the PRV combination therapy in the induction therapy phase in patients with previously untreated MCL.
- Trial name
- NCT06522386
- Testing
- Pirtobrutinib, Rituximab, Venetoclax
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia
Phase I Study Of PLM-102 In Patients With Relapsed And Refractory Acute Myeloid Leukemia
The goal of this clinical research study is to find the highest tolerable dose of PLM-102 that can be given to patients who have AML/MDS that is refractory and/or relapsed. The safety of PLM-102 will also be studied.
- Trial name
- NCT07549464
- Testing
- PLM-102
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- M.D. Anderson Cancer Center
Phase 1, SAR445877
Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer
To learn if SAR445877 in combination with FOLFOX6 and bevacizumab can be safely given to patients with advanced MSS CRC.
- Conditions
- Phase 1, SAR445877, FOlfox6, Bevacizimab
- Trial name
- NCT07500298
- Testing
- SAR445877, FOLFOX6, Bevacizumab
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- M.D. Anderson Cancer Center
Myeloma Multiple
Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
To increase the conversion rate from MRD-positive to MRD-negative CR in patients with newly diagnosed multiple myeloma (NDMM) receiving post-transplant maintenance therapy with belantamab mafodotin plus lenalidomide.
- Trial name
- NCT05091372
- Testing
- Belantamab mafodotin, Lenalidomide
- Where
- United States
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Neoadjuvant Treatment, Thyroid Cancer
Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
To look at the effectiveness of zanzalintinib, followed by surgery, in treating advanced thyroid cancer. The safety of this treatment will also be studied.
- Trial name
- NCT06959511
- Testing
- Zanzalintinib
- Where
- 4 sites in United States
- Volunteers
- 45 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, HOX Gene
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
To learn if revumenib (also known as SNDX-5613) can help to control leukemias associated with an increase in expression of HOX genes.
- Trial name
- NCT06229912
- Testing
- Revumenib
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Gliomas
Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas
To learn if the study drug, ulixertinib, can cross over the blood-brain barrier in patients with recurrent brain tumors
- Trial name
- NCT05804227
- Testing
- Ulixertinib
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer
To learn about the effectiveness of adding talazoparib to the standard of care treatment combination of androgen ablation therapy (hormone therapy, also known as ADT) and enzalutamide in patients with prostate cancer that has…
- Trial name
- NCT05873192
- Testing
- ADT, Enzalutamide, Talazoparib
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Randomized, Phase 2
Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma
To compare the time to next treatment between patients with previously untreated, low tumor burden FL who receive the study drug epcoritamab versus those who do not receive epcoritamab and are monitored only.
- Conditions
- Randomized, Phase 2, Epcoritamab, Watch & Wait
- Trial name
- NCT07783594
- Testing
- Epcoritamab, Observation
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
This phase Ib/II trial studies the best dose and side effects of venetoclax and how well it works when given with combination chemotherapy in treating patients with newly diagnosed acute myeloid leukemia or acute myeloid leukemia…
- Conditions
- High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Trial name
- NCT03214562
- Testing
- Cytarabine, Filgrastim, Fludarabine
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- M.D. Anderson Cancer Center
Select Advanced Solid Tumors
A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors
Phase 1 is to find the recommended dose of KSQ-004EX to give to participants with advanced solid tumors. Phase 2 is to learn if KSQ-004EX at the recommended dose found in Phase1 can help to control advanced solid tumors.
- Trial name
- NCT06598371
- Testing
- Cyclophosphamide, Fludarabine, KSQ-004EX
- Where
- United States
- Volunteers
- 141 people
- Sponsor
- M.D. Anderson Cancer Center
Malignant Solid Tumors
Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia
This is an open label, phase 2 study investigating asciminib in patients previously treated with one line of TKI therapy.
- Trial name
- NCT06629584
- Testing
- Asciminib
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.